Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company dedicated to the innovation, development, and delivery of tumor-infiltrating lymphocyte (TIL) therapy for cancer patients. Headquartered in San Carlos, California, the company's mission is to become a global leader in this field, pioneering a transformative approach that harnesses the human immune system to recognize and attack diverse cancer cells.

The company's key product is Amtagvi® (lifileucel), a tumor-infiltrating lymphocyte (TIL) therapy that received accelerated FDA approval in February 2024 for the treatment of unresectable or metastatic melanoma. Iovance also provides Proleukin, an interleukin-2 product that supports the Amtagvi treatment regimen. Beyond melanoma, Iovance is actively investigating TIL therapy in clinical trials for other advanced solid tumors, including non-small cell lung cancer, cervical cancer, and head and neck squamous cell carcinoma.

Recent notable developments include the conditional Australian approval for Amtagvi in advanced melanoma in June 2026, and FDA clearance to initiate the IOV-5001 trial for solid tumors. The company reported approximately $71 million in total revenue for Q1 2026, with projections of $86 million to $88 million for Q2 2026 and $350 million to $370 million for the full fiscal year 2026. Frederick G. Vogt serves as the Interim CEO.